

**Supplementary Table 1: Clinical, Laboratory, Imaging, Histologic, Features for Patients with Type 2 AIP**

Feature	Patient #1	Patient #2	Patient #3	Patient #4	Patient #5 *
<b>Demographics</b>	6-218-396	7-011-801	7-050-764	7-068-727	7-067-617
Age (years)	45	28	29	25	71
Gender	Male	Male	Male	Male	Female
<b>Presentation</b>	Recurrent pancreatitis & lingering abdominal pain	Abdominal pain	Obstructive jaundice (painless)	Abdominal pain	Obstructive jaundice (with abdominal pain)
<b>Laboratory</b>					
IgG <sub>4</sub> , <140mg/dL	146	119	N/A	33	40
CA 19-9, <55U/mL	35	N/A	N/A	<1	42
<b>Imaging</b>	CT: Normal (no evidence of AIP)	CT: Diffuse enlargement	CT: Normal (no evidence of AIP)	MRI: Diffuse enlargement (AIP considered)	Pancreatic head mass with diffuse enlargement (presumed cancer)
<b>Other Organ Involvement</b>	Ulcerative colitis	No	No	No	No
<b>Suspicion of AIP prior to EUS?</b>	AIP in Differential (but not specifically suspected)	AIP in Differential (but not specifically suspected)	AIP in Differential (but not specifically suspected)	No	No
<b>EUS</b>					
Appearance	Diffusely hypoechoic	Diffusely hypoechoic	Diffusely hypoechoic	Diffusely hypoechoic	Pancreatic head mass, diffusely hypoechoic
# FNA	0	3	2	2	2
Cytology	N/A	Negative	Negative	Negative	Negative
# TCB	3	2	3	7	3
Complications	No	No	No	No	No
<b>Histology (TCB)</b>					
GEL	Yes	Yes	No	Yes	Yes
Venulitis	Yes	Yes	Yes	Yes	Yes
LP infiltrate	Yes	Yes	Yes	Yes	Yes
Eosinophilia	Yes	No	No	Yes	Yes
Storiform fibrosis	Yes	Yes	Yes	Yes	Yes
>10 IgG4 cells/hpf	Yes	No	No	No	Yes
<b>Steroid Therapy</b>					
Regimen	Initial dose 40mg Taper over 4 months	Initial dose 20mg Taper over 2 weeks	Initial dose 40mg Taper over 4 months	Initial dose 40mg Taper over 4 months	Initial dose 40mg Taper over 3 months
Response	Complete	Complete	Complete	Complete	Complete
Evidence of response	Resolution of symptoms and CT changes	Resolution of symptoms (no follow-up CT)	Resolution of symptoms and CT changes	Resolution of symptoms (no follow-up CT)	Resolution of symptoms and CT changes
<b>Disease Recurrence</b>	No	No evidence, however	No	No	No

		undergoing evaluation for migratory arthralgia			
F/U duration (mo)	31	21	20	16	12

AIP Autoimmune pancreatitis

CT Computed tomography

EUS Endoscopic ultrasound

FNA Fine needle aspiration

GEL Granulocyte epithelial lesion

hpf High power field

IgG Immunoglobulin G

LP Lymphoplasmacytic

MRI Magnetic resonance imaging

TCB Trucut biopsy

\* Patient #5 underwent a prior EUS with FNA (n=3) that was negative and TCB (n=3) that revealed non-specific changes of chronic pancreatitis